Press Releases
May 5, 2021
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2021
April 28, 2021
Surface Oncology to Present Clinical Updates for SRF388 and SRF617
April 27, 2021
Surface Oncology Expands Leadership Team with Key Executive Appointment and Promotions
April 19, 2021
Surface Oncology Named a 2021 Best Places to Work Company by Boston Business Journal
April 9, 2021
Surface Oncology Presents Promising Preclinical Data for Lead Immunotherapy Product Candidates at the American Association for Cancer Research Annual Meeting
March 30, 2021
Surface Oncology’s SRF617 Receives Orphan Drug Designation from FDA for Treatment of Pancreatic Cancer
March 10, 2021
Surface Oncology to Present Preclinical Data for Lead Product Programs at the American Association for Cancer Research Annual Meeting
March 9, 2021
Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2020
March 9, 2021
Surface Oncology to Collaborate with Merck on Immuno-Oncology Study Evaluating SRF388, Targeting IL-27, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors
February 24, 2021
Surface Oncology to Participate in Upcoming March Investor Conferences
Displaying 1 - 10 of 12